Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ifosfamide combinations in lymphoma.

F Cabanillas1

  • 1Department of Hematology, M.D. Anderson Cancer Center, Houston, TX 77030.

Seminars in Oncology
|April 1, 1990
PubMed
Summary
This summary is machine-generated.

Ifosfamide and etoposide combinations showed significant response rates for lymphoma management. Long-term follow-up of the ifosfamide/methotrexate/etoposide regimen indicates durable disease-free survival for intermediate-grade lymphoma patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Curability Potential of Low-Grade Follicular Lymphoma.

Clinical lymphoma, myeloma & leukemia·2025
Same author

Rituximab Chimeric Anti-CD20 Monoclonal Antibody Therapy for Relapsed Indolent Lymphoma: Half of Patients Respond to a Four-Dose Treatment Program.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2023
Same author

Prospective trial of targeted radioimmunotherapy with Y-90 ibritumomab tiuxetan (Zevalin) for front-line treatment of early-stage extranodal indolent ocular adnexal lymphoma.

Annals of oncology : official journal of the European Society for Medical Oncology·2009
Same author

The addition of rituximab to CHOP chemotherapy improves overall and failure-free survival for follicular grade 3 lymphoma.

Annals of oncology : official journal of the European Society for Medical Oncology·2007
Same author

A phase I/II trial of pixantrone (BBR2778), methylprednisolone, cisplatin, and cytosine arabinoside (PSHAP) in relapsed/refractory aggressive non-Hodgkin's lymphoma.

Leukemia & lymphoma·2007
Same author

High incidence of non-neutropenic infections induced by rituximab plus fludarabine and associated with hypogammaglobulinemia: a frequently unrecognized and easily treatable complication.

Annals of oncology : official journal of the European Society for Medical Oncology·2006
Same journal

A systematic scoping review of cancer-related anemia treatment: Comparative trial outcomes, current guidelines, and future perspectives.

Seminars in oncology·2026
Same journal

Steroid-induced tumor lysis syndrome in solid tumors: A case report and review of the literature.

Seminars in oncology·2026
Same journal

PSMA PET/CT staging in intermediate-risk prostate cancer: Toward risk-adapted implementation.

Seminars in oncology·2026
Same journal

Angiogenesis and the corresponding antiangiogenic therapy in gastroenteropancreatic neuroendocrine neoplasms.

Seminars in oncology·2026
Same journal

Post-translational regulation of steroidogenesis and its clinical relevance in hormone responsive cancers.

Seminars in oncology·2026
Same journal

Physics-informed machine learning for tumor microenvironment-responsive nanomedicine: Recent updates.

Seminars in oncology·2026
See all related articles

Area of Science:

  • Oncology
  • Hematology
  • Clinical Pharmacology

Background:

  • Combination chemotherapy, specifically ifosfamide and etoposide, has been a cornerstone in lymphoma management.
  • The M.D. Anderson Cancer Center utilized these regimens for both newly diagnosed and relapsed lymphoma cases between 1977 and 1989.

Purpose of the Study:

  • To review the efficacy of various salvage regimens involving ifosfamide and etoposide for lymphoma.
  • To present preliminary data on the novel MINE (mesna, ifosfamide, novantrone, etoposide) regimen.
  • To report long-term (10-year) outcomes of the IMVP-16 (ifosfamide/methotrexate/etoposide) front-line protocol.

Main Methods:

  • Retrospective review of patient data from 1977-1989.
  • Analysis of response rates (overall and complete) and median survival times.

Related Experiment Videos

  • Inclusion of preliminary data for the MINE regimen and long-term follow-up for the IMVP-16 protocol.

    • Main Results:

    • Average overall response rates of 60% and complete response rates of 25% were observed.
    • Median survival was 9 months for relapsed intermediate-grade lymphoma and 12 months for low-grade lymphoma.
    • At 10-year follow-up, 62% of intermediate-grade lymphoma patients treated with IMVP-16 consolidation/intensification remained alive and disease-free.

    Conclusions:

    • Combination ifosfamide and etoposide regimens offer significant therapeutic benefits in lymphoma management.
    • The IMVP-16 protocol demonstrates promising long-term disease control for intermediate-grade lymphoma.
    • Further investigation into novel combinations like MINE is warranted.